Embecta Corp. (EMBC) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Parsippany, NJ, United States. Le PDG actuel est Devdatt Kurdikar.
EMBC a date d'introduction en bourse 2022-03-22, 2,000 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $560.22M.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
